Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alberto Orfao

Showing results (361-370 of 504) with videos related to

Pageof 51
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 16, 2011
Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myelomaBruno Paiva, Joaquin Martinez-Lopez, Maria-Belen Vidriales, et al.
Ebiomedicine|December 6, 2017
Proposed Terminology and Classification of Pre-Malignant Neoplastic Conditions: A Consensus ProposalPeter Valent, Cem Akin, Michel Arock, et al.
The Journal of Allergy and Clinical Immunology|August 8, 2013
Nonaggressive systemic mastocytosis (SM) without skin lesions associated with insect-induced anaphylaxis shows unique features versus other indolent SMIván Alvarez-Twose, Roberta Zanotti, David González-de-Olano, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 30, 2008
Prognostic value of immunophenotyping in multiple myeloma: a study by the PETHEMA/GEM cooperative study groups on patients uniformly treated with high-dose therapyGema Mateo, M Angeles Montalbán, Maria-Belén Vidriales, et al.
Blood|June 20, 2015
Critical analysis of the stringent complete response in multiple myeloma: contribution of sFLC and bone marrow clonalityJoaquín Martínez-López, Bruno Paiva, Lucía López-Anglada, et al.
Blood Advances|June 17, 2026
KIT mutation and AHN-associated oncogenic profiles in systemic mastocytosis with an associated hematological neoplasmPaula Navarro-Navarro, Carlos Maria Fernandez Gimenez, Andrés C García-Montero, et al.
Hemasphere|February 24, 2021
Precision Medicine in Hematology 2021: Definitions, Tools, Perspectives, and Open QuestionsPeter Valent, Alberto Orfao, Stefan Kubicek, et al.
Cell Reports. Medicine|October 29, 2024
Integrative single-cell multi-omics of CD19-CAR<sup>pos</sup> and CAR<sup>neg</sup> T cells suggest drivers of immunotherapy response in B cell neoplasiasMercedes Guerrero-Murillo, Aina Rill-Hinarejos, Juan L Trincado, et al.
Biology|May 24, 2024
Paired Primary and Recurrent Rhabdoid Meningiomas: Cytogenetic Alterations, <i>BAP1</i> Gene Expression Profile and Patient OutcomePatricia Alejandra Garrido Ruiz, Álvaro Otero Rodriguez, Luis Antonio Corchete, et al.
Blood|February 7, 2014
Contribution of cerebrospinal fluid sCD19 levels to the detection of CNS lymphoma and its impact on disease outcomeCarmen Muñiz, Lourdes Martín-Martín, Antonio López, et al.
Pageof 51

Showing results (361-370 of 504) with videos related to

Sort By:
Pageof 51
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 16, 2011
Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myelomaBruno Paiva, Joaquin Martinez-Lopez, Maria-Belen Vidriales, et al.
Ebiomedicine|December 6, 2017
Proposed Terminology and Classification of Pre-Malignant Neoplastic Conditions: A Consensus ProposalPeter Valent, Cem Akin, Michel Arock, et al.
The Journal of Allergy and Clinical Immunology|August 8, 2013
Nonaggressive systemic mastocytosis (SM) without skin lesions associated with insect-induced anaphylaxis shows unique features versus other indolent SMIván Alvarez-Twose, Roberta Zanotti, David González-de-Olano, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 30, 2008
Prognostic value of immunophenotyping in multiple myeloma: a study by the PETHEMA/GEM cooperative study groups on patients uniformly treated with high-dose therapyGema Mateo, M Angeles Montalbán, Maria-Belén Vidriales, et al.
Blood|June 20, 2015
Critical analysis of the stringent complete response in multiple myeloma: contribution of sFLC and bone marrow clonalityJoaquín Martínez-López, Bruno Paiva, Lucía López-Anglada, et al.
Blood Advances|June 17, 2026
KIT mutation and AHN-associated oncogenic profiles in systemic mastocytosis with an associated hematological neoplasmPaula Navarro-Navarro, Carlos Maria Fernandez Gimenez, Andrés C García-Montero, et al.
Hemasphere|February 24, 2021
Precision Medicine in Hematology 2021: Definitions, Tools, Perspectives, and Open QuestionsPeter Valent, Alberto Orfao, Stefan Kubicek, et al.
Cell Reports. Medicine|October 29, 2024
Integrative single-cell multi-omics of CD19-CAR<sup>pos</sup> and CAR<sup>neg</sup> T cells suggest drivers of immunotherapy response in B cell neoplasiasMercedes Guerrero-Murillo, Aina Rill-Hinarejos, Juan L Trincado, et al.
Biology|May 24, 2024
Paired Primary and Recurrent Rhabdoid Meningiomas: Cytogenetic Alterations, <i>BAP1</i> Gene Expression Profile and Patient OutcomePatricia Alejandra Garrido Ruiz, Álvaro Otero Rodriguez, Luis Antonio Corchete, et al.
Blood|February 7, 2014
Contribution of cerebrospinal fluid sCD19 levels to the detection of CNS lymphoma and its impact on disease outcomeCarmen Muñiz, Lourdes Martín-Martín, Antonio López, et al.
Pageof 51